Surrozen (NASDAQ:SRZN) Upgraded at Wall Street Zen

Surrozen (NASDAQ:SRZN) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts have also issued reports on SRZN. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $40.00 target price on shares of Surrozen in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. Finally, HC Wainwright restated a “buy” rating and issued a $36.00 price objective (up from $32.00) on shares of Surrozen in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Surrozen currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Surrozen Trading Up 3.2%

Shares of SRZN opened at $28.90 on Friday. Surrozen has a 12-month low of $5.90 and a 12-month high of $29.59. The stock has a market cap of $247.70 million, a P/E ratio of -0.87 and a beta of 0.53. The company has a 50-day moving average of $24.67 and a two-hundred day moving average of $19.00.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) EPS for the quarter, missing the consensus estimate of ($1.29) by ($6.30). Surrozen had a negative net margin of 7,476.67% and a negative return on equity of 1,240.42%. The business had revenue of $0.53 million during the quarter, compared to analyst estimates of $0.66 million. As a group, analysts forecast that Surrozen will post -8.49 EPS for the current fiscal year.

Insider Activity

In other news, Director Tim Kutzkey acquired 18,052 shares of Surrozen stock in a transaction that occurred on Tuesday, January 20th. The shares were acquired at an average price of $19.60 per share, with a total value of $353,819.20. Following the completion of the purchase, the director owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This represents a 1.81% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Group Gp Lp Column III acquired 18,052 shares of Surrozen stock in a transaction that occurred on Tuesday, January 20th. The shares were purchased at an average cost of $19.60 per share, for a total transaction of $353,819.20. Following the purchase, the insider directly owned 1,016,658 shares of the company’s stock, valued at approximately $19,926,496.80. This trade represents a 1.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 330,291 shares of company stock valued at $7,478,785 over the last 90 days. Insiders own 45.18% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Millennium Management LLC boosted its holdings in shares of Surrozen by 557.1% during the fourth quarter. Millennium Management LLC now owns 721,266 shares of the company’s stock worth $16,301,000 after purchasing an additional 611,497 shares during the last quarter. Stempoint Capital LP increased its stake in Surrozen by 185.1% in the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after purchasing an additional 445,713 shares during the last quarter. Spruce Street Capital LP acquired a new position in Surrozen in the fourth quarter valued at $9,764,000. Kalehua Capital Management LLC purchased a new position in Surrozen during the fourth quarter worth about $8,705,000. Finally, Braidwell LP lifted its position in Surrozen by 235.7% during the fourth quarter. Braidwell LP now owns 470,000 shares of the company’s stock worth $10,622,000 after buying an additional 330,000 shares during the period. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen News Roundup

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buying: TCG Crossover GP II purchased 106,658 shares on March 24 (~$2.63M at ~$24.69) as part of a recent string of purchases, materially increasing its stake and signaling insider conviction that can support the stock. InsiderTrades: Major Shareholder Purchases
• Positive Sentiment: Follow-on insider buy: TCG Crossover also bought 15,223 shares on March 23 at ~$24.90 (SEC filing disclosed), reinforcing the same insider-buy signal. American Banking News: Tcg Crossover Acquires Shares
• Positive Sentiment: Analyst support: Cantor Fitzgerald gave an “Overweight” rating and a $40 target, and HC Wainwright reiterated a “Buy” and raised targets/longer-term EPS forecasts — both items tend to attract buyer interest and can lift sentiment. American Banking News: Cantor Fitzgerald Rating American Banking News: HC Wainwright Buy Rating
• Positive Sentiment: HC Wainwright commentary on FY2030 shows a materially less-negative multi-year EPS path in their model (raises to FY2026–FY2029/FY2030 estimates), suggesting improving operating/profitability assumptions versus consensus. American Banking News: HC Wainwright FY2030 Comments
• Neutral Sentiment: Short-interest / days-to-cover data in some reports appears inconsistent (some sources show zero shorts / NaN), so treat short-interest as unreliable in explaining the move today.
• Negative Sentiment: Lifesci Capital cut near-term EPS estimates across Q1–Q4 2026 and trimmed FY2026, signaling more conservative short-term cash/burn or program timing assumptions — a reminder of execution and cash-risk that could cap upside. MarketBeat: Analyst Estimate Changes

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.